- Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Interventions
- 3,4-diaminopyridine
- Drug
- Lead sponsor
- Louis H. Weimer, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–14
of 14
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Total Knee Arthroplasty, Rehabilitation
- Interventions
- Anti-gravity treadmill, PENS - neuro-muscular stimulation, Anti-gravity treadmill & PENS - neuro-muscular stimulation, Recumbent or Nu-step bike
- Other
- Lead sponsor
- MedStar National Rehabilitation Network
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4 DAP
- Drug
- Lead sponsor
- David P. Richman, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 3 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Myasthenia Gravis, MuSK, AChR Myasthenia Gravis
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Philadelphia, Pennsylvania
- Conditions
- Myasthenic Syndromes, Congenital
- Interventions
- amifampridine phosphate, Placebo
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
- Conditions
- Lambert-Eaton Myasthenic Syndrome
- Interventions
- Amifampridine Phosphate, Placebo Oral Tablet
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Botulism, Iatrogenic Botulism
- Interventions
- Amifampridine
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Muscle Weakness
- Interventions
- 3-4 Diaminopyridine
- Drug
- Lead sponsor
- Jeffrey A. Cohen, MD
- Other
- Eligibility
- 45 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome
- Interventions
- Continuous 3,4-DAP, Taper 3,4-DAP to Placebo
- Drug
- Lead sponsor
- Jacobus Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 7
- States / cities
- Sacramento, California • Indianapolis, Indiana • Durham, North Carolina + 4 more
- Conditions
- Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired
- Interventions
- Amifampridine Phosphate
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Obesity
- Interventions
- Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lambert Eaton Myasthenic Syndrome
- Interventions
- 3, 4-Diaminopyridine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Aurora, Colorado